相关实验视频
Updated: Jun 17, 2025
06:20
Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
Published on: October 4, 2022
2.7K
通过MNK抑制选择性和有效地抑制胰腺癌
1Department of Oncology, Xiangyang Central Hospital, Hubei University of Arts and Science, Xiangyang, People's Republic of China.
Immunopharmacology and immunotoxicology
|August 14, 2024
概括
MNK-eIF4E-β-catenin通路驱动胰腺癌的生长和对治疗的抵抗. 与eFT508一样,抑制MNK激酶为胰腺癌提供了向治疗,并减少了副作用.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症信号传递 癌症信号传递
背景情况:
- 胰腺癌的特点是失调的信号通路.
- Wnt/β-catenin通路与癌症进展和化学抵抗有关.
- 确定特定的分子标对于有效的胰腺癌治疗至关重要.
研究的目的:
- 研究Wnt/β-catenin信号通路在胰腺癌中的作用.
- 为了确定治疗向的正常和瘤细胞的差异化因素.
- 评估针对MNK-eIF4E-β-catenin轴的治疗潜力.
主要方法:
- 在胰腺组织中分析总和化真核转化启动因子4E (eIF4E) 和β-catenin.
- 功能性试验评估eIF4E酸化对β-catenin信号传递,扩散和化学抵抗的影响.
- 在体外和体内胰腺癌模型中对MNK激酶抑制剂eFT508的评估.
主要成果:
- 在胰腺癌组织中,eIF4E和β-catenin的水平升高.
- eIF4E酸化激活β-catenin信号,促进增殖和化学抵抗.
- eFT508治疗抑制了eIF4E酸化,抑制了β-catenin,并选择性地减少了瘤生长.
结论:
- MNK-eIF4E-β-catenin轴对胰腺癌的进展和化学抵抗至关重要.
- 这个轴作为正常和癌细胞之间的关键区分器.
- 用eFT508等抑制剂向MNK激酶是胰腺癌的一种有前途的治疗策略.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
01:22PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K